



**S/N 10/500,485**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Martin Bolli, et al	)	Examiner: Rao, Deepak R.
	)	
Serial No.: 10/500,485	)	Group Art Unit: 1624
	)	
Filed: June 29, 2004	)	Attorney Docket: AC-11-US
	)	
Title: Novel Alkansulfonamides as Endothelin Antagonists	)	

---

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In accordance with 37 C.F.R. §1.97 *et. seq.*, Applicant provides the enclosed materials for the Examiner's consideration in connection with the above-identified patent application.

Applicant respectfully requests that this Information Disclosure Statement and the documents listed on the attached Forms SB/08A and SB/08B and enclosed herewith be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the SB/08 forms, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Copies of foreign patent documents and non-patent documents are enclosed herein.

The information contained in this Information Disclosure Statement is not to be construed as a representation 1) that a search has been conducted; 2) that additional information material to


the examination of this application does not exist; 3) that the information, protocol, results and the like reported by third parties are accurate or enabling; 4) the information is considered to be material to patentability; or 5) that the information constitutes prior art to the current application.

It is believed that no fee is required. If a fee is required, please charge the same to Deposit Account No. 50-4255. The Examiner is invited to contact the Applicant's representative at the telephone number listed below if there are any questions.

Respectfully submitted,

Date:

7/27/07



Thomas Hoxie  
Reg. No. 32,993

HOXIE & ASSOCIATES LLC  
75 Main Street  
Suite 301  
Millburn, New Jersey 07041  
973-912-5232

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

**Complete if Known**

Application Number	10/500,485
Filing Date	06/29/2004
First Named Inventor	Martin Bolli
Art Unit	1624
Examiner Name	Rao, Deepak R.
Attorney Docket Number	AC-11-US

Sheet	1	of	2
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	<b>1</b>	WO0117976	03-15-2001	Actelion Pharmaceuticals		
	<b>2</b>	EP1191026	03-27-2002	Pfizer Limited, et al.		
	<b>3</b>	EP0743307	11-20-1996	Tanabe Seiyaku Co., Ltd.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/500,485
Filing Date	June 29, 2004
First Named Inventor	Martin Bolli
Art Unit	1624
Examiner Name	Rao, Deepak R.
Attorney Docket Number	AC-11-US

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	4	Harada, Hironori, et al., "Ethenesulfonamide and Ethanesulfonamide Derivatives, a Novel Class of Orally Active Endothelin-A Receptor Antagonists",	
	4	Bioorganic & Medicinal Chemistry, 2001, vol 9, pages 2955-2968	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.